Complications after transcatheter closure of patent ductus arteriosus

Young Jang Gi, Sung Son Chang, Won Lee Joo, Young Lee Jae, Jin Kim Soo

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)

Abstract

To evaluate the short- and mid-term results and complications ensuing the transcatheter closure of patent ductus arteriosus (PDA). Between October 1999 and December 2005, 117 patients (34 males and 83 females) underwent attempted percutaneous closure of PDA with a minimum diameter of more than 3 mm. Follow-up evaluations were conducted at 1 day and 1, 3, 6, 12 months after the performance of the transcatheter closure. The median age of patients at catheterization was 11 yr (range, 0.6 to 68 yr), median weight was 30 kg (range, 6 to 74 kg), and the median diameter of PDA was 4 mm (range, 3 to 8 mm). This procedure was conducted successfully in 114 patients (97.4%), using different devices. Major complications were detected in 4 patients (3.4%); significant hemolysis (2), infective endocarditis (1), failed procedure due to embolization (1). Minor complications occurred in 6 patients (5.1%); mild narrowing of the descending aorta (2) and mild encroachment on the origin of the left pulmonary artery (4). Although the transcatheter closure of PDA may be considered to be effective, several complications, including hemolysis, embolization, infective endocarditis, and the narrowing of adjacent vessels may occur in certain cases.

Original languageEnglish
Pages (from-to)484-490
Number of pages7
JournalJournal of Korean medical science
Volume22
Issue number3
DOIs
Publication statusPublished - 2007
Externally publishedYes

Bibliographical note

Funding Information:
Dr. Marco Puthenparampil, Dr. Davide Poggiali, Dr. Giuseppe Rolma and Dr. Francesco Causin received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. Dr. Francesca Rinaldi has received honoraria from Biogen Idec, Merk Serono and Teva. Dr. Paola Perini has received honoraria from Biogen Idec/Elan, Merck Serono, Sanofi-Aventis and Teva; has been a consultant for Biogen Idec, Merck Serono and Teva. Prof. Paolo Gallo has received honoraria from Bayer Schering, Biogen Idec/Elan, Merck Serono, Novartis, Sanofi-Aventis and Teva; has been a consultant for Bayer Schering, Biogen Idec, Genzyme, Merck Serono and Novartis; has received research support from Bayer, Biogen Idec/Elan, Merk Serono, Genzyme and Teva; and has received research grant from the University of Padova, Veneto Region of Italy, the Italian Association for Multiple Sclerosis, the Italian Ministry of Public Health.

Keywords

  • Catheterization
  • Complications
  • Patent ductus arteriosus

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Complications after transcatheter closure of patent ductus arteriosus'. Together they form a unique fingerprint.

Cite this